(332) Controlled Release of Fluticasone Propionate after Intra-Articular Injection of EP-104IAR in Sheep

Introduction: Knee osteoarthritis (KOA) is a degenerative joint disease with a global prevalence of 365 million cases [1]. EP-104IAR is a polymer-coated crystal of fluticasone propionate (FP) for the treatment of KOA pain. EP-104IAR achieves extended-release of FP by a diffusion-controlled mechanism resulting in reduced peak FP concentrations, FP exposure extended for weeks and prolonged therapeutic activity. A Phase 2 clinical trial of EP-104IAR in KOA patients has recently been completed [2]. We report the results of a pharmacokinetic and tolerability study of EP-104IAR injected into the stifle of sheep.